Management of chronic hepatitis B infection: Current treatment guidelines, challenges, and new developments

doi:10.3748/wjg.v20.i20.6262

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 20

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (14751)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-9) series.

Item

Count

PDF

1359

WORD

376

HTML

10603

Figures (1-2)

256

Tables (1-9)

153

Sum=12747

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1086

Download

918

Sum=2004

May 28, 2014 (publication date) through Apr 27, 2024

Times Cited of This Article

Times Cited (105)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. May 28, 2014; 20(20): 6262-6278
Published online May 28, 2014. doi: 10.3748/wjg.v20.i20.6262

Table 5 Comparison of de novo combination therapy and monotherapy

Combination therapy	Monotherapy	HBeAg seroconversion	HBV DNA	HBsAg clearance	Histological improvement	Drug resistance
LAM + ADV	LAM	=	=	N/A	=	↓
LAM + ADV	ETV	N/A	=	N/A	N/A	N/A
ETV + TDF	ETV	=	=	N/A	=	=
LAM + PEG-IFN	LAM	↑	↓	↑	↑	↓
ADV + PEG-IFN	PEG-IFN	N/A	↓	↑	N/A	N/A
ETV + PEG-IFN	ETV	↑	↓	↑	N/A	N/A

In several randomized controlled trials, combination therapy with nucleos(t)ide analogues and PEG-IFN are superior to existing management options with regards to viral load, HBeAg seroconversion, and HBsAg clearance. HBeAg: Hepatitis B e antigen; HBsAg: Hepatitis B surface antigen; PEG-IFN: Pegylated interferon; ETV: Entecavir; LAM: Lamivudine; ADV: Adefovir; TBV: Telbivudine; TDF: Tenofovir disoproxil fumarate; N/A: Not applicable.

Citation: Tang CM, Yau TO, Yu J. Management of chronic hepatitis B infection: Current treatment guidelines, challenges, and new developments. World J Gastroenterol 2014; 20(20): 6262-6278
URL: https://www.wjgnet.com/1007-9327/full/v20/i20/6262.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i20.6262